(Q46570247)

23 December 2017

title

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women (English)

1 reference

23 December 2017

0 references

1 reference

3

1 reference

23 December 2017

author name string

Steven Boonen

1

1 reference

23 December 2017

Deborah E Sellmeyer

2

1 reference

23 December 2017

Alexander Orlov-Morozov

4

1 reference

23 December 2017

Ken Abrams

5

1 reference

23 December 2017

Peter Mesenbrink

6

1 reference

23 December 2017

Erik F Eriksen

7

1 reference

23 December 2017

Paul D Miller

8

1 reference

23 December 2017

language of work or name

English

0 references

publication date

28 May 2008

1 reference

23 December 2017

published in

Kidney International

1 reference

23 December 2017

volume

74

1 reference

23 December 2017

issue

5

1 reference

23 December 2017

page(s)

641-648

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.1038/ki.2008.193

exact match

0 references

cites work

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Intravenous ibandronate: in the treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Transmission of human herpesvirus 8 by blood transfusion

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Zoledronic acid and clinical fractures and mortality after hip fracture

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Anticancer drug-induced kidney disorders

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Indexing glomerular filtration rate for body surface area in obese patients is misleading: concept and example.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Renal Failure with the Use of Zoledronic Acid

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Zoledronic Acid and renal toxicity: data from French adverse effect reporting database

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Safety of intravenous and oral bisphosphonates and compliance with dosing regimens

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Assessing kidney function--measured and estimated glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.193

7 January 2021

Identifiers

DOI

10.1038/KI.2008.193

1 reference

23 December 2017

1 reference

23 December 2017